Sarvagalla Sailu, Singh Vivek Kumar, Ke Yi-Yu, Shiao Hui-Yi, Lin Wen-Hsing, Hsieh Hsing-Pang, Hsu John T A, Coumar Mohane Selvaraj
Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, 605014, Puducherry, India.
J Comput Aided Mol Des. 2015 Jan;29(1):89-100. doi: 10.1007/s10822-014-9807-2. Epub 2014 Oct 26.
Furanopyrimidine 1 (IC50 = 273 nM, LE = 0.36, LELP = 10.28) was recently identified by high-throughput screening (HTS) of an in-house library (125,000 compounds) as an Aurora kinase inhibitor. Structure-based hit optimization resulted in lead molecules with in vivo efficacy in a mouse tumour xenograft model, but no oral bioavailability. This is attributed to "molecular obesity", a common problem during hit to lead evolution during which degradation of important molecular properties such as molecular weight (MW) and lipophilicity occurs. This could be effectively tackled by the right choice of hit compounds for optimization. In this regard, ligand efficiency (LE) and ligand efficiency dependent lipophilicity (LELP) indices are more often used to choose fragment-like hits for optimization. To identify hits with appropriate LE, we used a MW cut-off <250, and pyrazole structure to filter HTS library. Next, structure-based virtual screening using software (Libdock and Glide) in the Aurora A crystal structure (PDB ID: 3E5A) was carried out, and the top scoring 18 compounds tested for Aurora A enzyme inhibition. This resulted in the identification of a novel tetrahydro-pyrazolo-isoquinoline hit 7 (IC50 = 852 nM, LE = 0.44, LELP = 8.36) with fragment-like properties suitable for further hit optimization. Moreover, hit 7 was found to be selective for Aurora A (Aurora B IC50 = 35,150 nM) and the possible reasons for selectivity investigated by docking two tautomeric forms (2H- and 3H-pyrazole) of 7 in Auroras A and B (PDB ID: 4AF3) crystal structures. This docking study shows that the major 3H-pyrazole tautomer of 7 binds in Aurora A stronger than in Aurora B.
呋喃嘧啶1(IC50 = 273 nM,LE = 0.36,LELP = 10.28)最近通过对一个内部库(125,000种化合物)进行高通量筛选(HTS)被鉴定为一种极光激酶抑制剂。基于结构的命中优化产生了在小鼠肿瘤异种移植模型中具有体内疗效但无口服生物利用度的先导分子。这归因于“分子肥胖”,这是命中到先导进化过程中的一个常见问题,在此过程中会发生重要分子性质如分子量(MW)和亲脂性的降解。通过正确选择用于优化的命中化合物可以有效解决这个问题。在这方面,配体效率(LE)和配体效率依赖性亲脂性(LELP)指数更常用于选择类似片段的命中物进行优化。为了鉴定具有合适LE的命中物,我们使用分子量截止值<250和吡唑结构来筛选HTS库。接下来,在极光A晶体结构(PDB ID:3E5A)中使用软件(Libdock和Glide)进行基于结构的虚拟筛选,并对得分最高的18种化合物进行极光A酶抑制测试。这导致鉴定出一种新型的四氢吡唑并异喹啉命中物7(IC50 = 852 nM,LE = 0.44,LELP = 8.36),其具有适合进一步命中优化的类似片段性质。此外,发现命中物7对极光A具有选择性(极光B的IC50 = 35,150 nM),并通过将7的两种互变异构形式(2H-和3H-吡唑)对接在极光A和B(PDB ID:4AF3)晶体结构中来研究选择性的可能原因。该对接研究表明,7的主要3H-吡唑互变异构体在极光A中的结合比在极光B中更强。